Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma

Cutaneous T-Cell Lymphoma (CTCL) has a chronic, relapsing course with patients undergoing multiple, consecutive therapies. Treatment aims at the clearance of skin disease, minimization of recurrence, prevention of disease progression and preservation of quality of life. The treatment of CTCL is primarily determined by the disease extent. Prolonged complete remissions have been obtained with skin-directed therapies in early stage Mycosis fungoides (MF) (IA-IIA), whereas advanced stages CTCL (IIB-IVB) are often refractory to treatment and, thus, have an unfavorable prognosis. Currently, there

Trial Details

NCT ID
NCT04128072
Phase
PHASE2
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Mogamulizumab
  • Total Skin Electron Beam Therapy (TSEB)
  • Mogamulizumab (subsequent cycles post TSEB)
Locations (sample)
  • Copenhagen, Denmark|55.67594,12.56553
  • Bordeaux, France|44.84124,-0.58046
  • Paris, France|48.85341,2.3488
  • Mannheim, Germany|49.4891,8.46694
  • Minden, Germany|52.28953,8.91455

Key Eligibility Criteria

  • Diagnosis of MF stage IB, IIA or IIB at registration, and MF stage should have never met criteria for stage IIIA or higher.
  • Subjects who have failed (refractory or relapsed) at least one prior course of systemic therapy.
  • All clinically significant toxic effects of prior cancer therapy to grade ≤ 1 according to the National Cancer Institute Common Terminology Criteri…
  • Males and female subjects ≥ 18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →